CRP and fungal infectious disease: This prospective study enrolled 64 hematological hospitalized patients to receive chemotherapy. These had proven or probable invasive fungal infection or microbiologically proven bacterial bloodstream infection. In total, 53 patients with bacterial bloodstream infections and 11 with invasive fungal infections participated in the study. Results showed that a combination of CRP >120 with PCT <1.25 or presepsin <170 could be a possible combined biomarker for invasive fungal infections in immunocompromised patients.